Noteworthy diabetes management products and updates making waves this year.
Like other areas of healthcare, diabetes management in 2019 has been experiencing a combination of new device developments and improvements, technological advancements, new drug approvals, and new partnerships offering a glimpse of distant future possibilities.Â Here are five noteworthy products and updates that are making waves in the diabetes management space this year:
The OmniPod Dash + APP from Insulet is a simple two-part system consisting of a tubeless, wireless, waterproof, and Bluetooth-enabled wireless technology pod that can hold up 22 units of U-100 insulin; and a modern, color touchscreen Personal Diabetes Manager that controls the pod. A small, flexible cannula inserts automatically with the push of a button.
The FDA recently cleared the OmniPod DASH system as an Alternate Controller Enabled Infusion (ACE) Pump. According to the FDA, the pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, and to receive, execute, and confirm commands from external devices.
This in vitro diagnostic test is the first test that can be used to diagnose and monitor patients with diabetes or pre-diabetes at the point of care in about three minutes.
Blood samples are automatically diluted and mixed with a solution that releases hemoglobin from erythrocytes, creating precipitation. The sample mixture is then transferred to a blue boronic acid conjugate, which binds to the cis-diols of glycated hemoglobin. The mixture is then soaked through a filter membrane that collects precipitated hemoglobin and conjugate-bound and -unbound remains. Excess conjugate is removed with a washing agent.
The FDA recently approved oral tablet administrations of Novo Nordisk’s Ozempic (semaglutide) under the new product name Rebylsus.
7 mg and 14 mg tablets are now available for the treatment of patients with type 2 diabetes that, along with diet and exercise, are believed to improve blood glucose levels.
According to a release, the tumors developed in rodent trials, but the potential for c-cell tumor development in humans with the use of semaglutide is still unknown.
Semaglutide is contraindicated in patients with a personal or familial history of MTC or in patients with multiple endocrine neoplasia syndrome type 2, according to a boxed warning in the product’s prescribing information.
Adverse reactions reported with the use of semaglutide include nausea, abdominal pain, diarrhea, decreased appetite, vomiting, and constipation.
Abbott and Sanofi have recently partnered to combine the former’s FreeStyle Libre technology with the latter’s insulin dosing information for future smart pens, insulin titration apps, and cloud computing software.
FreeStlye Libre reads glucose levels through a sensor worn on the back of the upper arm, thereby eliminating the need for finger sticks.
The LibreLink App enables users to capture and view real-time glucose levels, eight-hour glucose history, and glucose level changes in real time on their smartphone.
AgaMatrix-a New Hampshire-based company developing, manufacturing, and marketing solutions for blood glucose monitoring data management on mobile and cloud platforms and
LifeWallet-a digital healthcare company-have announced a new partnership to integrate AgaMatrix’s Bluetooth blood glucose monitoring systems with LifeWallet’s apps for health risk assessment and follow up care.
The integration with occur through Apple’s Healthkit, and will also allow clinicians to monitor patients’ daily habits and compliance to a tailored care plan through LifeWallet’s Engage App.
LifeWallet is also currently piloting a Sugar Smart for Life Program with West Kendall Baptist Church.